The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: A patent review

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 6, 2012, Pages 645-661

  Pinto, Donald J P ^a   Qiao, Jennifer X ^a   Knabb, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Acute coronary syndrome; Anticoagulant; Antithrombotic; Apixaban; Atrial fibrillation; Betrixaban; Deep vein thrombosis; Edoxaban; Factor Xa inhibitor; Rivaroxaban; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ATECEGATRAN METOXIL; AZD 8165; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; LETAXABAN; LIXIANA; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; ORGANONITROGEN DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ASTHMA; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; IC 50; INFORMATION RETRIEVAL; MEDLINE; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STROKE; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BINDING SITES; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; DRUG DESIGN; FACTOR XA; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862275055     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.680438     Document Type: Review

References (97)

1. Pinto DJP, Smallheer JM, Cheney DL, et al.Factor Xa Inhibitors: next-Generation Antithrombotic Agents.J Med Chem 2010;53:6243-74
2. Jackson SP.Arterial thrombosis-insidious, unpredictable and deadly.Nature Medicine 2011;17:1423-36
3. Ansell J, Hirsh J, Hylek E, et al.Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence based clinical practice guidelines (8th edition).Chest 2008;133:160S-98S
4. Blossom DB, Kallen AJ, Patel PR, et al.Outbreak of adverse reactions associated with contaminated heparin.N Engl J Med 2008;359:2674-84
5. Lip GY, Lim HS.Atrial fibrillation and stroke prevention.Lancet Neurol 2007;6:981-93
6. Spyropoulos AC, Merli G.Management of venous thromboembolism in the elderly.Drugs Aging 2006;23:651-71
7. Wong PC, Crain EJ, Xin B, et al.Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.J Thromb Haemost 2008;6:820-9
8. Wong PC, Crain EJ, Watson CA, et al.Nonpeptide Factor Xa Inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.J Pharmacol Exp Ther 2002;303:993-1000
9. Brighton TA.The direct thrombin inhibitor melagatran/ximelagatran.Med J Aust 2004;18:432-7
10. Fiessinger JN, Huisman MV, Davidson BL, et al.For the THRIVE Treatment Study Investigators.Ximelagatran vs.low molecular weight heparin and warfarin for the treatment of deep vein thrombosis: randomized trial.JAMA 2005;293:681-9
11. Shulman S, Wahlander K, Lundstrom T, et al.for the THRIVE III Investigators.Secondary prevention of venous thromboembolism with the direct thrombin inhibitor ximelagatran.N Engl J Med 2003;349:1713-21
12. Wallentin L, Wilcox RG, Weaver W, et al.for the ESTEEM Investigators.Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial.Lancet 2003;362:789-97
13. Halperin JL.Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.A randomized trial.JAMA 2005;293:690-8
14. Eriksson BI, Dahl OE, Rosencher N, et al.Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.Lancet 2007;370:949-56
15. Eriksson BI, Dahl OE, Rosencher N, et al.RE-MODEL Study Group.Oral dabigatran etexilate vs.subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.J Thromb Haemost 2007;5:2178-85
16. Schulman S, Kearon C, Kakkar AK, et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism.N Engl J Med 2009;361:2342-52
17. Schulman S, Kakkar AK, Schellong SM, et al.A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II).American Society of Hematology 2011 Annual Meeting; December 12, 2011; San Diego, CA.Abstract 205
18. Hauel NH, Nar H, Priepke H, et al.Structure-based design of novel potent nonpeptide thrombin inhibitor.J Med Chem 2002;45:1757-66
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al.for the RE-LY Steering Committee and Investigators.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med 2009;361:1139-51
20. Verheugt WA.Novel oral anticoagulants to prevent stroke in atrial fibrillation.Nat Rev Cardiol 2010;7:149-54
21. Eriksson BI, Borris L, Dahl OE, et al.ODIXa-HIP Study Investigators.Oral, direct factor Xa inhibition with BAY 59-7939 For the prevention of venous thromboembolism after total hip replacement.J Thromb Haemost 2006;4:121-8
22. Eriksson BI, Borris L, Dahl OE, et al.ODIXa-HIP Study Investigators.A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.Circulation 2006;114:2374-81
23. Eriksson BI, Borris L, Dahl OE, et al.Dose-escalation study of rivaroxaban (BAY 59-7939); an oral, direct factor Xa inhibitor; for the prevention of venous thromboembolism in patients undergoing total hip replacement.Thromb Res 2007;120:685-93
24. Fisher WD, Eriksson BI, Bauer KA, et al.Rivaroxaban for thromboprophylaxis after orthopedic surgery: pooled analysis of two studies.Thromb Haemost 2007;97:931-7
25. Turpie AG, Fisher WD, Bauer KA, et al.ODIXa-KNEE Study Group.BAY 59- 7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement.A phase II dose-ranging study.J Thromb Haemost 2005;3:2479-86
26. Eriksson BI, Borris LC, Friedman RJ, et al.RECORD1 Study Group.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.N Engl J Med 2008;358:2765-75
27. Buller HR, Lensing AWA, Prins MH, et al.Einstein-DVT Dose-Ranging Study Investigators.A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study.Blood 2008;112:2242-7
28. Patel MR, Mahaffey KW, Garg J, et al.Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation.N Engl J Med 2011;365:883-91
29. Mega JL, Braunwald E, Wiviott SD, et al.Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med 2011;366:9-19
30. Lassen MR, Gallus AS, Pineo GF, et al.The ADVANCE-2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement.J Thromb Haemost 2009;7:LB-MO-005
31. Lassen MR, Raskob GE, Gallus A, et al.Apixaban or enoxaparin for thromboprophylaxis after knee replacement.N Engl J Med 2009;361:594-604
32. Lassen MR, Gallus A, Raskob GE, et al.Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.N Engl J Med 2010;63:2487-98
33. Connolly SJ, Eikelboom J, Joyner C, et al.Apixaban in patients with atrial fibrillation.N Engl J Med 2011;364:806-17
34. Granger CB, Alexander JH, McMurray JJV, et al.Apixaban versus Warfarin in Patients with Atrial Fibrillation.N Engl J Med 2011;365:981-92
35. http://www.portola.com/Betrixaban
36. Ansell J.Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5:60-4
37. Turpie AG.Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.Arterioscler Thromb Vasc Biol 2007;27:1238-47
38. Wong PC, Crain EJ, Watson CA, et al.Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.J Thromb Haemost 2009;7:1313-20
39. Reverter JC.Fondaparinux sodium.Drugs Today (Barc.) 2002;38:185-94
40. Sculpher MJ, Lozano-Ortega G, Sambrook J, et al.Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.Am Heart J 2009;157:845-52
41. Peters RJG, Joyner C, Bassand JP, et al.and OASIS-6 Investigators.The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.Eur Heart J 2008;29:324-31
42. Yusuf S, Mehta SR, Chrolavicius S, et al.Comparison of fondaparinux and enoxaparin in acute coronary syndromes.N Engl J Med 2006;354:1464-76
43. Straub A, Roehrig S, Hillisch A.Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? Angew Chem Int Ed 2011;50:4574-91
44. Lee Y-K, Player MR.Developments in Factor Xa inhibitors for the treatment of thromboembolic disorders.Med Res Rev 2011;31:202-83
45. Alexander D, Jeremias A.Rivaroxaban in the contemporary treatment of acute coronary syndromes.Expert Opin Investig Drugs 2011;20:849-57
46. Eriksson BI, Quinlan DJ, Eikelboom JW.Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.Annu Rev Med 2011;62:41-57
47. Casimiro-Garcia A, Dudley DA, Heemstra RJ, et al.Progress in the discovery of FXa inhibitors.Expert Opin Ther Patents 2006;16:119-45
48. Modesto de Candia M, Gianfranco LG, Altomare C.Novel factor Xa inhibitors: a patent review.Expert Opin Ther Patents 2009;19:1535-80
49. Bayer Schering Pharma Aktiengesellschaft, Germany & Janssen Pharmaceutical N.V.Oxazolidinones for the treatment and/or prophylaxis of heart failure.WO2009074249; 2009
50. Bayer Schering Pharma Aktiengesellschaft, Germany.Oxazolidinones for the treatment of chronic obstructive pulmonary disease (COPD) and/or asthma.EP2138178, WO2009156082; 2009
51. Bayer Schering Pharma A.-G., Germany.Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract.EP2140866, Chemical Indexing Equivalent to WO2010000404; 2010
52. Bayer Schering Pharma AG.New co-crystal compound of rivaroxaban and malonic acid.WO2009149851; 2009
53. Apotex Pharmachem, INC.Process for the preparation of rivaroxaban and intermediates thereof.US20110034465; 2011
54. KRKA NOVO MESTO DD.Process for crystallization of rivaroxaban. WO2011012321; 2011
55. Ratiopharm GMBH.Pharmaceutical compositions comprising rivaroxaban.EP2308472; 2011
56. Ratiopharm GMBH.Pharmaceutical composition with modified release properties useful for treating e.g.infarct, stroke and lung embolism comprises rivaroxaban, solubilizer, non-erodible polymer and pore-forming substance.WO2010017948; 2010
57. Ratiopharm GMBH.Pharmaceutical compositions comprising 5-chloro-N-(((5S)- 2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)- 1,3-oxazolidin-5-yl)-methyl)-2- thiophencarboxamid.WO2010003641; 2010
58. Apotex Pharmachem, INC.Polymorphic form of 5 Chloro N {[(5S) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxazolidin 5 yl]-methyl}thiophene 2 carboxamide.US20100168111; 2011
59. SANDOZ AG.Method for the preparation of rivaroxaban.WO11098501A, EP2354128; 2011
60. Enatia SI.Process for the preparation of rivaroxaban and intermediates thereof.WO11080341; 2011
61. Bayer Pharma Aktiengesellschaft.Method for producing substituted pyridin-2-one.WO2011134963; 2011
62. Bayer Healthcare AG.Substituted (oxazolidinon-5-yl-methyl)-2- thiophenecarboxamide and use thereof in the field of blood coagulation. WO2008155032; 2008
63. Boehringer Ingelheim International GmbH.Substituted amides, manufacturing and use thereof as medicaments.WO2009063028; 2009
64. Boehringer Ingelheim International GmbH.Substituted amides, manufacturing and use thereof as medicaments.WO2009063029; 2009
65. Legochem Bioscience Co., Ltd.FXa inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, process for their preparations and pharmaceutical compositions and derivatives thereof.WO2010002115; 2010
66. Bioscience Co., Ltd.Method for preparing (S)-5-chloro-N-({3-[4-(5,6- dihydro-4H-1,2,4- oxadiazin-3-yl)phenyl]-2-oxooxazolidin-5-yl} methyl)thiophene-2-carboxamide derivatives.WO2011005028; 2011
67. Green Cross Corp, S.Korea; LegoChem Bioscience Co., Ltd.Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6- dihydro-4H-[1,2,4]triazin-1-yl) phenyl]- 1,3-oxazolidin-5-yl}methyl)thiophene-2- carboxamide derivative and intermediate used therein.WO2011005029; 2011
68. Concert Pharmaceuticals, Inc.Substituted oxazolidinone derivatives.WO2009023233; 2009
69. Bristol-Myers Squibb Co. & Pfizer, Inc., USA.Dosage forms of apixaban.WO2010147978; 2010
70. Auspex Pharmaceuticals, Inc.Pyrazole carboxamide inhibitors of factor Xa.WO2010030983; 2010
71. Protia LLC.Deuterium-enriched apixaban.US20090076069; 2009
72. Daiichi Sankyo Co., Ltd.Method for producing optically active diamine derivative.WO2010104106; 2010
73. Daiichi Sankyo Co., Ltd.Process to produce optically active carboxylic acid derivative.WO2010067824; 2010
74. Daiichi Sankyo Co., Ltd.Activated blood coagulation factor Xa (FXa) inhibitors.WO2010071164; 2010
75. Daiichi Sankyo Co., Ltd.Method for producing diamine derivative. WO2010071121; 2010
76. Daiichi Sankyo Co., Ltd.Pharmacologically acceptable salt of [1,3,4]oxadiazole compound or hydrate thereof.WO2010058751; 2010
77. Daiichi Sankyo Co., Ltd.Novel diamide derivative.JP2010120852L; 2010
78. Portola Pharmaceuticals, Inc., USA.Antidotes for factor Xa inhibitors and methods of using the same.WO2009042962; 2009
79. Portola Pharmaceuticals, Inc., USA.Antidotes for factor Xa inhibitors and methods of using the same.US20100255000; 2010
80. Portola Pharmaceuticals, Inc., USA.Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents.WO2010056765; 2010
81. Portola Pharmaceuticals, Inc., USA.Unit dose formulation of antidotes for factor X inhibitors and methods of using the same.WO2011008885; 2011
82. Cadila Healthcare Ltd, India.Sulfoximine derivatives as factor Xa inhibitors.WO2009053999; 2010
83. Tovbin, Dmitry Gennadlevich, Russian.Urethanes, ureas, amidines and related inhibitors of factor Xa.WO2011108963; 2011
84. Novel acylated decasaccharides and their use as antithrombotic agents.WO2010128450; 2010
85. SANOFI-AVENTIS.Novel acylated 1,6- anhydro decasaccharide and its use as antithrombotic agent.WO2010128446; 2010
86. SANOFI-AVENTIS.Novel sulfated heptasaccharide and its use as antithrombotic agent.WO2010128447; 2010
87. SANOFI-AVENTIS.Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain.WO2010023375; 2010
88. SANOFI-AVENTIS.Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain.WO2010023374; 2010
89. United States Dept.of Health and Human Services, USA.Sand fly salivary proteins as factor Xa inhibitors and methods of use as anticoagulants. WO2010078469; 2010
90. Coinfar - Consorcio de Industrias Farmaceuticas, Brazil.Kunitz-type recombinant factor.US20090042786; 2009
91. Sanofi-Aventis.Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin.WO2009103440; 2009
92. Sanofi-Aventis.Chlorothiopheneisoxazoles as inhibitors of coagulation factors Xa and thrombin.WO2009103439; 2009
93. Ajinomoto Co., Inc., Japan.Amidine derivatives.WO2010005087; 2010
94. Univ North Carolina at Chapel hill.Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues.WO2009014715; 2009
95. Uchrezhdenie RAN Institut Khimii Khimicheskoi.Tekhnologii SO RAN, Russia; Uchrezhdenie RAMN.Gematologicheskii Nauchnyi Tsentr RAMN.Anticoagulant. RU2399377; 2010
96. Virginia Commonwealth University, USA.Cinnamic acid-based oligomers and uses thereof.WO2010027594; 2010
97. Schebo Biotech AG, Germany.Novel pharmaceuticals, method for the production thereof, and use thereof in therapy.WO2009018807; 2009